Literature DB >> 1873082

Maturation of human immunodeficiency virus particles assembled from the gag precursor protein requires in situ processing by gag-pol protease.

E K Ross1, T R Fuerst, J M Orenstein, T O'Neill, M A Martin, S Venkatesan.   

Abstract

The vaccinia virus expression system was used to determine the role of human immunodeficiency virus type 1 (HIV-1) protease in viral morphogenesis and maturation. The unprocessed p55 gag precursor polyprotein alone was assembled to form HIV-1 particles which budded from cells. The particles were spherical and immature, containing an electron-dense shell in the particle submembrane; there was no evidence of core formation. Expression of both gag and pol proteins from a recombinant containing the complete gag-pol coding sequences resulted in intracellular processing of gag-pol proteins and the production of mature particles with electron-dense cores characteristic of wild-type HIV virions. To ascertain the role of protein processing in particle maturation, the pol ORF in the gag-pol recombinant was truncated to limit expression of the pol gene to the protease domain. With this recombinant expressing p55 gag and protease, intracellular processing was observed. Some of the resultant particles were partially mature and contained processed gag protein subunits. In contrast, particle maturation was not observed when the HIV-1 protease and p55 gag were coexpressed from separate recombinants, despite evidence of intracellular gag processing. These findings suggest that HIV-1 protease must be an integral component of the full-length gag-pol precursor for optimal processing and virion maturation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1873082     DOI: 10.1089/aid.1991.7.475

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  14 in total

1.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Mutations in the primer grip of human immunodeficiency virus type 1 reverse transcriptase impair proviral DNA synthesis and virion maturation.

Authors:  Q Yu; M Ottmann; C Pechoux; S Le Grice; J L Darlix
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

3.  Cryoelectron microscopic examination of human immunodeficiency virus type 1 virions with mutations in the cyclophilin A binding loop.

Authors:  L B Kong; D An; B Ackerson; J Canon; O Rey; I S Chen; P Krogstad; P L Stewart
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Role of the major homology region of human immunodeficiency virus type 1 in virion morphogenesis.

Authors:  F Mammano; A Ohagen; S Höglund; H G Göttlinger
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.

Authors:  E O Freed; J M Orenstein; A J Buckler-White; M A Martin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Functional domains of the capsid protein of human immunodeficiency virus type 1.

Authors:  T Dorfman; A Bukovsky; A Ohagen; S Höglund; H G Göttlinger
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Incorporation of Pr160(gag-pol) into virus particles requires the presence of both the major homology region and adjacent C-terminal capsid sequences within the Gag-Pol polyprotein.

Authors:  M Huang; M A Martin
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

9.  Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors.

Authors:  A Dulioust; S Paulous; L Guillemot; A M Delavalle; F Boué; F Clavel
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.

Authors:  N T Parkin; M Chamorro; H E Varmus
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.